Wells Fargo lowered the firm's price target on Metagenomi to $9 from $12 and keeps an Overweight rating on the shares. Following the company's Q1 update, the firm notes that MGX-001 for Hemophilia A continues to progress on track, with an IND filing anticipated in Q4 2026 and initiation of a Phase 1/2 trial in 2027.
